Literature DB >> 12050154

Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice.

Marina Mattiazzi1, Marilena D'Aurelio, Carl D Gajewski, Katherine Martushova, Mahmoud Kiaei, M Flint Beal, Giovanni Manfredi.   

Abstract

A growing body of evidence suggests that impaired mitochondrial energy production and increased oxidative radical damage to the mitochondria could be causally involved in motor neuron death in amyotrophic lateral sclerosis (ALS) and in familial ALS associated with mutations of Cu,Zn superoxide dismutase (SOD1). For example, morphologically abnormal mitochondria and impaired mitochondrial histoenzymatic respiratory chain activities have been described in motor neurons of patients with sporadic ALS. To investigate further the role of mitochondrial alterations in the pathogenesis of ALS, we studied mitochondria from transgenic mice expressing wild type and G93A mutated hSOD1. We found that a significant proportion of enzymatically active SOD1 was localized in the intermembrane space of mitochondria. Mitochondrial respiration, electron transfer chain, and ATP synthesis were severely defective in G93A mice at the time of onset of the disease. We also found evidence of oxidative damage to mitochondrial proteins and lipids. On the other hand, presymptomatic G93A transgenic mice and mice expressing the wild type form of hSOD1 did not show significant mitochondrial abnormalities. Our findings suggest that G93A-mutated hSOD1 in mitochondria may cause mitochondrial defects, which contribute to precipitating the neurodegenerative process in motor neurons.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12050154     DOI: 10.1074/jbc.M203065200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  220 in total

Review 1.  Mitochondrial dysfunction in familial amyotrophic lateral sclerosis.

Authors:  Liesbeth Faes; Geert Callewaert
Journal:  J Bioenerg Biomembr       Date:  2011-12       Impact factor: 2.945

2.  Increased axonal mitochondrial mobility does not slow amyotrophic lateral sclerosis (ALS)-like disease in mutant SOD1 mice.

Authors:  Yi-Bing Zhu; Zu-Hang Sheng
Journal:  J Biol Chem       Date:  2011-04-25       Impact factor: 5.157

Review 3.  Neuronal degeneration and mitochondrial dysfunction.

Authors:  Eric A Schon; Giovanni Manfredi
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

Review 4.  Complex genetics of amyotrophic lateral sclerosis.

Authors:  Catherine B Kunst
Journal:  Am J Hum Genet       Date:  2004-10-11       Impact factor: 11.025

Review 5.  Links between electrophysiological and molecular pathology of amyotrophic lateral sclerosis.

Authors:  Katharina A Quinlan
Journal:  Integr Comp Biol       Date:  2011-10-11       Impact factor: 3.326

Review 6.  Import, maturation, and function of SOD1 and its copper chaperone CCS in the mitochondrial intermembrane space.

Authors:  Hibiki Kawamata; Giovanni Manfredi
Journal:  Antioxid Redox Signal       Date:  2010-11-01       Impact factor: 8.401

7.  Activation of Ets-2 by oxidative stress induces Bcl-xL expression and accounts for glial survival in amyotrophic lateral sclerosis.

Authors:  Junghee Lee; Mari Kannagi; Robert J Ferrante; Neil W Kowall; Hoon Ryu
Journal:  FASEB J       Date:  2009-01-29       Impact factor: 5.191

8.  The Psi(m) depolarization that accompanies mitochondrial Ca2+ uptake is greater in mutant SOD1 than in wild-type mouse motor terminals.

Authors:  Khanh T Nguyen; Luis E García-Chacón; John N Barrett; Ellen F Barrett; Gavriel David
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-27       Impact factor: 11.205

Review 9.  Mitochondrial approaches for neuroprotection.

Authors:  Rajnish K Chaturvedi; M Flint Beal
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

10.  Neuronal glucose metabolism is impaired while astrocytic TCA cycling is unaffected at symptomatic stages in the hSOD1G93A mouse model of amyotrophic lateral sclerosis.

Authors:  Tesfaye W Tefera; Karin Borges
Journal:  J Cereb Blood Flow Metab       Date:  2018-03-19       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.